Seven Bridges’ experts share new developments in big data and cancer research at two April events

Back to Press Releases

Seven Bridges’ experts share new developments in big data and cancer research at two April events

CEO Deniz Kural to Present at Bio-IT World and Scientific Program Manager Brandi Davis-Dusenbery Joins AACR Annual Meeting

CAMBRIDGE, Mass. — 5 April 2016 — Seven Bridges, the biomedical data analysis company, today announced several upcoming speaking engagements where CEO Deniz Kural and scientific program manager Brandi Davis-Dusenbery will discuss new developments in precision medicine and cancer research informatics.

At the Bio-IT World Conference & Expo (April 5-7 in Boston) and the American Association for Cancer Research (AACR) Annual Meeting (April 16-20 in New Orleans), Deniz and Brandi will respectively share insights from several national-scale projects — including the National Cancer Institute’s Cancer Genomics Cloud (CGC)pilot — that are using cloud-based technologies to analyze massive volumes of genomic data and accelerate research on novel cancer treatments. Details on the upcoming presentations are as follows:


Building National-Scale Genomics Projects with Collaborative, Portable, Reproducible Analysis

WHO: Deniz Kural, CEO, Seven Bridges

Bio-IT World, Seaport World Trade Center, Boston, MA


Thursday, April 7, 11:40 a.m. ET


NCI’s Cancer Genomics Cloud Pilots – NCI/NIH-Sponsored Session

WHO: Brandi Davis-Dusenbery, Scientific Program Manager, Seven Bridges

AACR Annual Meeting, Morial Convention Center, New Orleans, LA

WHEN: Sunday, April 17, 3:45 p.m. CT

During their presentations, Deniz and Brandi will discuss the computational challenges involved in analyzing hundreds of thousands of whole genomes, and explore novel technology approaches that are being deployed to overcome them. They will also share some of the stories resulting from Seven Bridges’ recent Cancer Genomics Cloud Hackathon.

Hosted in collaboration with the National Institutes of Health’s (NIH) Big Data to Knowledge (BD2K) Initiative, the early April event brought together more than 50 cancer biomedical researchers, data scientists and clinicians from Harvard, MIT, Yale, UCSC and beyond to build portable cancer analysis tools on the Cancer Genomics Cloud, using data from The Cancer Genomics Atlas (TCGA).

“As the use of next-generation sequencing in cancer research and discovery continues to explode, demand for information on how to scale, accelerate and more effectively collaborate on national-scale genomics projects is growing,” said James Sietstra, President of Seven Bridges. “The success of our recent Hackathon and interest in the latest developments in NGS informatics underscores the momentum we are seeing with the Cancer Genomics Cloud, the 100,000 Genomes Project, and other cloud initiatives. It’s an exciting time to work in cancer research.”

About Seven Bridges

Seven Bridges is the biomedical data analysis company accelerating breakthroughs in genomics research for cancer, drug development and precision medicine. The scalable, cloud-based Seven Bridges Platform empowers rapid, collaborative analysis of millions of genomes in concert with other forms of biomedical data. Thousands of researchers in government, biotech, pharmaceutical and academic labs use Seven Bridges, including four of the largest genomics projects in the world: U.S. National Cancer Institute’s Cancer Genomics Cloud pilot, the Million Veteran Program, the Children’s Hospital of Philadelphia’s Cavatica project and Genomics England’s 100,000 Genomes Project. As the NIH’s only commercial Trusted Partner, Seven Bridges authenticates and authorizes access to one of the world’s largest cancer genomics datasets. The company has offices in Cambridge, Mass.; Belgrade; London and San Francisco.


Press Contacts